[Treatment perspectives for critical limb ischemia: gene and cell therapy].
Critical limb ischemia is associated with a high risk of amputation and death. Several medical options have been tested on patients who cannot be revascularized surgically, but none has shown any effect on the amputation rate at 6 months.Gene and cell therapy intended to stimulate angiogenesis have been tested in phase I and II clinical trials. These innovative approaches appear both feasible and safe. Large randomized clinical trials are necessary to demonstrate their benefits and long-term safety.
Pasqualoni
Elisa
E
Service de médecine vasculaire - HTA, Hôpital européen Georges Pompidou, F75908 Paris Cedex 15, France.
Messas
Emmanuel
E
Fiessinger
Jean-Noël
JN
Emmerich
Joseph
J
D017690:Cell Transplantation; D016638:Critical Illness; D015316:Genetic Therapy; D006801:Humans; D007511:Ischemia / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D018919:Neovascularization, Physiologic